second- and third-generation tkis in egfr-mutated nsclc
Published 5 years ago • 90 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
8:30
third-generation egfr inhibitors in nsclc
-
4:48
third-generation egfr inhibitors in nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
0:49
exploring advantages to third-generation tkis in lung cancer
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
5:28
egfr-mutated nsclc; where we are now?
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
4:28
overcoming resistance to egfr inhibitors in nsclc
-
3:45
azd9291 and rociletinib in t790m-mutant nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
3:07
third generation egfr tkis for acquired resistance
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
3:25
are there significant differences among the 1st and 2nd generation egfr tkis?
-
7:51
nsclc: egfr inhibition and resistance mechanisms
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc